FDA Clarifies Marketing Exclusivity Policy for Generic Drugs

Summary

The FDA is publishing a document to clarify its practices governing 180 days of marketing exclusivity for generic drugs and the approval of abbreviated new drug applications, following recent court decisions on the 1984 amendments to the Drug Price Competition and Patent Term Restoration Act.